Maximum Dose of Amiodarone Drip
The maximum infusion rate for intravenous amiodarone is 1 mg/min during the initial 6-hour period, followed by a maintenance rate of 0.5 mg/min, with the initial infusion rate not to exceed 30 mg/min during bolus administration. 1
Standard Dosing Protocol
The FDA-approved dosing regimen for IV amiodarone follows a structured approach over the first 24 hours 1:
First 24 Hours
- Loading bolus: 150 mg IV over 10 minutes (can be repeated in 10-30 minutes if necessary) 2
- Initial infusion: 1 mg/min for 6 hours
- Maintenance infusion: 0.5 mg/min for 18 hours
- Total first 24-hour dose: Approximately 1000 mg 1
Beyond 24 Hours
- Maintenance rate: 0.5 mg/min (720 mg per 24 hours) can be continued for 2-3 weeks 1
- The maintenance infusion rate may be increased to achieve effective arrhythmia suppression 1
Critical Safety Considerations
Maximum Rate Warnings
Do not exceed an initial infusion rate of 30 mg/min 1. This is crucial because:
- Intravenous amiodarone loading infusions at concentrations and rates much higher than recommended have resulted in hepatocellular necrosis and acute renal failure leading to death 1
- In controlled clinical trials, mean daily doses above 2100 mg were associated with increased risk of hypotension 1
Concentration Limits
- For infusions longer than 1 hour, do not exceed 2 mg/mL concentration unless using a central venous catheter 1
- Concentrations greater than 3 mg/mL are associated with high incidence of peripheral vein phlebitis 1
- Always use a central venous catheter for concentrations greater than 2 mg/mL 1
Supplemental Dosing for Breakthrough Arrhythmias
For breakthrough episodes of VF or hemodynamically unstable VT:
- 150 mg supplemental bolus mixed in 100 mL D5W
- Infuse over 10 minutes to minimize hypotension 1
- This can be repeated as needed 3
Common Pitfalls to Avoid
Infusion pump requirement: Amiodarone MUST be delivered by volumetric infusion pump, not drop counters, as drop size reduction can lead to 30% underdosing 1
Hypotension risk: Treatment-emergent hypotension occurred in 16% of patients in clinical studies 2. Monitor blood pressure closely, especially during bolus administration
Bradycardia: Symptomatic bradycardia is a significant adverse effect 2. Have pacing capability available
Prolonged therapy: Limited experience exists for IV amiodarone beyond 3 weeks 1. Transition to oral therapy when appropriate
Administration Requirements
- Use glass or polyolefin bottles (not evacuated glass containers) 1
- Use in-line filter during administration 1
- Administer through dedicated central venous catheter whenever possible 1
- Solution concentrations of 1-6 mg/mL are acceptable, but lower concentrations preferred for peripheral access 1
The evidence consistently supports these maximum rates across multiple guidelines 2, 4, 5, 6 and the FDA label 1, with the primary concern being the balance between achieving therapeutic effect and avoiding serious adverse events including hypotension, bradycardia, and hepatotoxicity.